Abstract
c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf protein was detected in 15 ovarian cancer cell lines. Antisense oligodeoxynucleotides (ODNs) (ISIS 5132 and ISIS 13650) reduced c-Raf protein levels and inhibited cell proliferation in vitro. Selectivity was demonstrated by the lack of effect of ISIS 5132 on A-Raf or ERK, while a random ODN produced only minor effects on growth and did not influence c-Raf expression. ISIS 5132 produced enhanced apoptosis and cells accumulated in S and G(2)/M phases of the cell cycle. In vivo, ISIS 5132 inhibited growth of the s.c. SKOV-3 xenograft while a mismatch ODN had no effect. These data indicate that high levels of c-Raf expression may be important in ovarian cancer and use of antisense ODNs targeted to c-Raf could provide a strategy for the treatment of this disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1753-8 |
| Number of pages | 6 |
| Journal | British Journal of Cancer |
| Volume | 85 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 30 Nov 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Cell Cycle/drug effects
- Cell Division/drug effects
- DNA, Antisense/pharmacology
- Dose-Response Relationship, Drug
- Female
- Humans
- Immunohistochemistry
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Ovarian Neoplasms/drug therapy
- Proto-Oncogene Proteins c-raf/biosynthesis
- Survival Analysis
- Time Factors
- Xenograft Model Antitumor Assays
Fingerprint
Dive into the research topics of 'Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver